AB Science announces that results from AB8939 preclinical program in acute myeloid leukemia will be presented at the European...
11 June 2020 - 5:23AM
Paris, 10 June 2020, 9pm
Results from AB8939 preclinical program in
acute myeloid leukemia presented at the European Hematology
Association (EHA) 2020 Annual Congress
AB Science SA (Euronext -
FR0010557264 - AB) today announces that an abstract reporting
results from its AB8939 preclinical development program in acute
myeloid leukemia (AML), is to be presented as an e-Poster at the
European Hematology Association (EHA) 2020 Annual Congress.
Entitled, ‘AB8939, a Novel
Microtubule-Destabilizing Agent for the Treatment of Acute Myeloid
Leukemia’, this e-Poster presentation will be made available on the
on-demand Virtual Congress platform as of Friday, June 12 at 08:30
CEST and will be accessible until October 15, 2020.
The Annual Congress of EHA is a flagship meeting
that encompasses the entire spectrum of hematological studies. The
Annual Congress regularly attracts 11,000 participants and experts
from across the globe. Due to the current COVID-19 pandemic, EHA
will deliver this year’s Congress as a Virtual Edition, consisting
of pre-recorded content. The virtual congress program can be viewed
via the following link:
https://ehaweb.org/congress/eha25/program/.
The therapeutic potential of AB8939 in AML is
demonstrated using Ara-C resistant and azacitidine resistant
patient-derived xenograft (PDX) models. Ara-C is considered the
clinically most relevant cytotoxic agent for AML treatment, while
azacitidine is a widely used hypomethylating agent for AML.
“Overall, these results support development of
AB8939 as a treatment of relapsed/refractory AML patients unable to
receive intensive chemotherapy, which is a particularly vulnerable
group with a high unmet medical need” commented Professor Olivier
Hermine (lead author of the abstract and member of the Académie des
Sciences in France). “Important mechanisms of action for AB8939 in
AML are that it can overcome P-glycoprotein mediated resistance
and, remarkably for a microtubule inhibitor, it is not deactivated
by the myeloperoxidase (MPO) myeloid enzyme.”
Key findings include:
- AB8939 overcomes P-glycoprotein (Pgp) and myeloperoxidase (MPO)
mediated resistance
- AB8939 is active in Ara-C resistant/refractory AML, with
activity seen across all AML subtypes
- AB8939 alone or combined with Ara-C, improved survival and
reduced disease burden relative to Ara-C alone
- AB8939 is active in azacitidine resistant AML, with greatly
reduced hematotoxicity relative to azacitidine
About AB8939AB8939 is a novel
microtubule destabilizing agent that is differentiated from other
drugs of this class primarily by its inability to be transported by
P-glycoprotein, thereby having potential to overcome Pgp-dependent
multidrug resistance in cancer patients.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, and inflammatory diseases. The
company is headquartered in Paris, France, and listed on Euronext
Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB ScienceThis
press release contains forward-looking statements. These statements
are not historical facts. These statements include projections and
estimates as well as the assumptions on which they are based,
statements based on projects, objectives, intentions and
expectations regarding financial results, events, operations,
future services, product development and their potential or future
performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents filed by AB Science with the
Autorité des Marchés Financiers (AMF), including those listed in
the Chapter 4 "Risk Factors" of AB Science reference document filed
with the AMF on November 22, 2016, under the number R. 16-078. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
Ab Science (EU:AB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ab Science (EU:AB)
Historical Stock Chart
From Apr 2023 to Apr 2024